Alembic Pharma shares surge 20% on USFDA nod for depression drug

Representative Image

Shares of Alembic Pharmaceuticals today surged 20 per cent after the company received the US health regulator's nod for Bupropion Hydrochloride tablets, used for treatment of major depressive disorder.

The stock soared 19.87 per cent to settle at Rs 521.25 on BSE. During the day, it jumped 19.99 per cent to Rs 521.80.

On NSE, shares of the company zoomed 20 per cent to close at Rs 522.30.

The company's market valuation also rose by Rs 1,629.39 crore to Rs 9,826.39 crore.

"The company has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Bupropion Hydrochloride tablets," Alembic Pharmaceuticals said in a BSE filing.

The approval is for strengths of 75 mg and 100 mg.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel